Cytosorbents Corp. (CTSO) Stock Price
CTSOStock
$4.11−77.32%52W
Market Cap$12.95M
P/E—
PEG Ratio—
Div yield—
Beta1.51
CTSO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-75.02%
Price vs S&P 500 (4W)-24.08%
VGM Score42.60
CTSO Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.90 | -$1.40 | -55.56%(-$0.50) | |
| Q1 2026 | -$1.10 | -$1.60 | -45.45%(-$0.50) | |
| Q4 2025 | -$1.00 | -$1.80 | -80.00%(-$0.80) | |
| Q3 2025 | -$0.93 | -$1.00 | -7.14%(-$0.07) | |
| Q2 2025 | -$0.06 | $0.03 | +152.94%(+$0.09) |
CTSO Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
2.17
2.17
2.17
2.17
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
CTSOCytosorbents Corp. | B | D | D | 0.3x | -2.0% | 71.6% | -36.2% | $4.11 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About Cytosorbents Corp.
CytoSorbents develops proprietary polymer adsorption technology to treat life-threatening conditions in intensive care and cardiac surgery. Its EU-approved flagship product, CytoSorb, functions as an extracorporeal cytokine absorber designed to reduce inflammation and prevent multiple organ failure in critical illnesses such as sepsis and trauma. The company generates revenue from product sales across Germany and the United States, supplemented by government grants, with distribution through direct sales and strategic partnerships.